HIF1A and acquired polycythemia vera: Moreover, IL-6 and JAK1/2 inhibitor Ruxolitinib significantly increased angiogenic factors—eNOS (Figure 1A), VEGF (Figure 1B), and HIF-1α (Figure 1C—in PV patients.